Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis by Kotecha, Dipak et al.
 
 
University of Birmingham
Efficacy of  blockers in patients with heart failure
plus atrial fibrillation
Kotecha, Dipak; Holmes, Jane; Krum, Henry; Altman, Douglas G; Manzano, Luis; Cleland,
John G F; Lip, Gregory Y H; Coats, Andrew J S; Andersson, Bert; Kirchhof, Paulus; von
Lueder, Thomas G; Wedel, Hans; Rosano, Giuseppe; Shibata, Marcelo C; Rigby, Alan;
Flather, Marcus D; Beta-Blockers in Heart Failure Collaborative Group
DOI:
10.1016/S0140-6736(14)61373-8
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Kotecha, D, Holmes, J, Krum, H, Altman, DG, Manzano, L, Cleland, JGF, Lip, GYH, Coats, AJS, Andersson, B,
Kirchhof, P, von Lueder, TG, Wedel, H, Rosano, G, Shibata, MC, Rigby, A, Flather, MD & Beta-Blockers in Heart
Failure Collaborative Group 2014, 'Efficacy of  blockers in patients with heart failure plus atrial fibrillation: an
individual-patient data meta-analysis', The Lancet, vol. 384, no. 9961, pp. 2235-43.
https://doi.org/10.1016/S0140-6736(14)61373-8
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This Author Accepted Manuscript Version is subject to a Creative Commons Attribution Non-Commercial No Derivatives license after 6
months from publication.
Checked September 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
 
Efficacy of beta-blockers in patients with heart failure plus atrial 
fibrillation: An individual-patient data meta-analysis 
 
Dipak Kotecha1,2,3, Jane Holmes4, Henry Krum3, Douglas G Altman4, Luis Manzano5,           
John GF Cleland6,7, Gregory YH Lip1,8, Andrew JS Coats9,10, Bert Andersson11,                    
Paulus Kirchhof1,8,12, Thomas G von Lueder3,13, Hans Wedel14, Giuseppe Rosano15,              
Marcelo C Shibata16, Alan Rigby17 and Marcus D Flather18,                                                           
on behalf of the Beta-Blockers in Heart Failure Collaborative Group. 
 
 
 
Beta-Blockers in Heart Failure Collaborative Group 
 
 
 
 
Published in The Lancet (online 02 September 2014). 
 
Citation:  Kotecha D, Holmes J, Krum H, et al. Efficacy of ß blockers in patients with heart 
failure plus atrial fibrillation: An individual-patient data meta-analysis.  Lancet 2014; 
DOI:10.1016/S0140-6736(14)61373-8. 
 
Link to The Lancet:  Early Online Publication 
 
Pubmed ID:  25193873 
 
 
 
 
 
  
Author institutions: 
 
From the (1) University of Birmingham Centre for Cardiovascular Sciences, Birmingham, 
UK; (2) Clinical Trials & Evaluation Unit, Royal Brompton & Harefield NHS Trust, London, 
UK; (3) Centre of Cardiovascular Research and Education in Therapeutics, Monash 
University, Melbourne, Australia; (4) Centre for Statistics in Medicine, University of Oxford, 
Oxford, UK; (5) Internal Medicine Department, Hospital Universitario Ramón y Cajal, 
Universidad de Alcalá, Madrid, Spain; (6) National Heart & Lung Institute, Royal Brompton 
& Harefield Hospitals, Imperial College, London; (7) Hull York Medical School, University 
of Hull, Kingston upon Hull, UK; (8) City Hospital, Sandwell & West Birmingham NHS 
Trust, Birmingham, UK; (9) Monash University, Melbourne, Australia; (10) Warwick 
University, Warwick, UK; (11) Department of Cardiology, Sahlgrenska University Hospital, 
Gothenburg, Sweden; (12) Department of Cardiovascular Medicine, University Hospital 
Münster, Münster, Germany; (13) Department of Cardiology, Oslo University Hospital, Oslo, 
Norway; (14) Nordic School of Public Health, Gothenburg, Sweden; (15) Department of 
Medical Sciences, IRCCS San Raffaele Pisana, Roma, Italy; (16) Division of Cardiology, 
University of Alberta, Edmonton, Canada; (17) Academic Cardiology, Castle Hill Hospital, 
Kingston upon Hull, UK; and (18) Norwich Medical School, University of East Anglia, 
Norwich, UK.  
 
 
 
 
Address for correspondence: 
Dr Dipak Kotecha  
University of Birmingham Centre for Cardiovascular Sciences,  
The Medical School, Vincent Drive, Edgbaston, Birmingham, B15 2TT, United Kingdom. 
Email:    d.kotecha@bham.ac.uk  
 
  
 
 
  
Abstract 
 
Background:  Atrial fibrillation and heart failure often coexist, causing substantial 
cardiovascular morbidity and mortality.  Beta blockers are indicated in patients with 
symptomatic heart failure with reduced ejection fraction; however, the efficacy of these drugs 
in patients with concomitant atrial fibrillation is uncertain.  We therefore meta-analysed 
individual-patient data to assess the efficacy of beta blockers in patients with heart failure and 
sinus rhythm compared with atrial fibrillation. 
 
Methods:  We extracted individual-patient data from ten randomised controlled trials of the 
comparison of beta blockers versus placebo in heart failure.  The presence of sinus rhythm or 
atrial fibrillation was ascertained from the baseline electrocardiograph.  The primary outcome 
was all-cause mortality.  Analysis was by intention to treat.  Outcome data were meta-
analysed with an adjusted Cox proportional hazards regression.  
 
Findings: 18 254 patients were assessed, and of these 13 946 (76%) had sinus rhythm and 
3066 (17%) had atrial fibrillation at baseline.  Crude death rates over a mean follow-up of 1·5 
years (SD 1·1) were 16% (2237 of 13 945) in patients with sinus rhythm and 21% (633 of 
3064) in patients with atrial fibrillation.  Beta-blocker therapy led to a significant reduction in 
all-cause mortality in patients with sinus rhythm (hazard ratio 0·73, 0·67–0·80; p<0·001), but 
not in patients with atrial fibrillation (0·97, 0·83–1·14; p=0·73), with a significant p value for 
interaction of baseline rhythm (p=0·002).  The lack of efficacy for the primary outcome was 
noted in all subgroups of atrial fibrillation, including age, sex, left ventricular ejection 
fraction, New York Heart Association class, heart rate, and baseline medical therapy. 
 
Interpretation:  Based on our findings, beta blockers should not be used preferentially over 
other rate-control medications and not regarded as standard therapy to improve prognosis in 
patients with concomitant heart failure and atrial fibrillation. 
 
Registration:  PROSPERO CRD42014010012; Clinicaltrials.gov NCT00832442. 
 
Abbreviations 
ACEi   Angiotensin converting enzyme inhibitor 
ARB    Angiotensin receptor blocker 
AF   Atrial fibrillation 
CI   Confidence interval 
CV   Cardiovascular 
ECG   Electrocardiogram 
GFR   Glomerular filtration rate 
HF   Heart failure 
HR   Hazard ratio 
IPD   Individual patient data 
LVEF   Left-ventricular ejection fraction 
NYHA   New York Heart Association  
OR   Odds ratio 
RCT   Randomised controlled trial 
Introduction 
Beta-blocker therapy for patients with chronic heart failure (HF) with reduced ejection 
fraction was instituted following a series of small mechanistic studies that led to large 
randomised controlled trials (RCTs) identifying a significant reduction in morbidity and 
mortality.  Their use in symptomatic patients with HF has a class 1A recommendation from 
both European and American guidelines.1, 2  Nonetheless, uptake of therapy in clinical 
practice remains sub-optimal, with those at the greatest risk of death less likely to receive 
evidence-based therapy.3  There have also been concerns over treatment efficacy in certain 
groups, notably patients with atrial fibrillation (AF), women and the elderly.  Previous 
analyses in these important patient subsets have lacked statistical power and further 
randomised evidence is now unlikely.  The Beta-blockers in Heart Failure Collaborative 
Group was formed to provide definitive answers to a range of unanswered questions relating 
to HF and beta-blocker therapy, with the aim of optimising use and providing clear guidance 
on the efficacy and safety of treatment.4 
 
Chronic HF and AF represent two common conditions that are associated with substantial 
morbidity and risk of death.1, 5  Importantly, both are predicted to continue increasing in 
prevalence6, 7, with the incidence of AF expected to double in the next 20 years.8   
Rehospitalisation is seen in over 50% of patients with HF within 6 months9 and in nearly 
40% of AF patients over 12 months.10  Despite improved medical therapy, HF remains a 
significant driver of healthcare cost.11  Those with concomitant AF have even higher 
mortality and hospital admission rates, regardless of which condition comes first.12, 13  In 
addition, the prevalence of AF is closely related to the severity of HF, as determined by 
NYHA functional class.14   
 
We sought to examine the efficacy and safety of beta-blockers in patients with HF and 
concomitant AF by performing an individual patient data (IPD) meta-analysis.  Patients with 
AF are frequently prescribed beta-blockers both for prognostic benefit in HF and heart-rate 
control, although there is limited and underpowered evidence for efficacy with regards to 
clinical outcomes.15  Considered the ‘gold-standard’ of meta-analysis, IPD allows appropriate 
examination of sub-groups and the ability to accurately combine original data (thereby 
improving data quality), perform full time-to-event analyses and generate hazard ratios 
adjusted for baseline covariates.16  Assessment of over 18,000 patients randomised to beta-
blockers or placebo permits a robust and adequately-powered analysis of the clinical benefit 
of beta-blocker therapy in patients with HF and AF, compared to those in sinus rhythm.  
Methods 
A detailed rationale and design paper has previously been published (click here for link to 
free online publication).4  To summarise, the Beta-blockers in Heart Failure Collaborative 
Group (BB-meta-HF) is a multinational effort to combine individual data from the major 
RCTs investigating the use of beta-blockers in HF.  The group consists of the leading 
investigators of these trials and international experts, with the support of the four 
pharmaceutical companies that have marketed therapies (AstraZeneca, GlaxoSmithKline, 
Merck Serono and Menarini).  This report was prepared according to the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines17 and prospectively 
registered with Clinicaltrials.gov (NCT0083244) and the PROSPERO database of systematic 
reviews (CRD42014010012).18 
 
Eligibility, search strategy and data collection 
Published or unpublished RCTs were identified through computer aided searches (e.g. 
Medline and Current Contents), scrutiny of reference lists of trials, trials registries, meeting 
abstracts, review articles as well as discussion with group members and pharmaceutical 
manufacturers.  RCTs were included that reported mortality as a primary or composite 
outcome comparing beta-blockers versus placebo.  Only unconfounded head-to-head trials 
were eligible, with recruitment of >300 patients and planned follow-up of >6 months to make 
the project technically feasible and clinically-relevant.  The search results, individual study 
demographics and a standardised data request form to obtain IPD from each trial have 
previously been published.4   
Eleven studies were included that account for 95.7% of eligible recruited participants: the 
Australia/New Zealand Heart Failure Study (ANZ)19, the Beta-Blocker Evaluation Survival 
Trial (BEST)20, the Carvedilol Post-Infarct Survival Control in LV Dysfunction Study 
(CAPRICORN)21, the Carvedilol Hibernating Reversible Ischaemia Trial: Marker of Success 
Study (CHRISTMAS)22, the Cardiac Insufficiency Bisoprolol Study (CIBIS I)23, the Cardiac 
Insufficiency Bisoprolol Study II (CIBIS-II)24, the Carvedilol Prospective Randomized 
Cumulative Survival Study (COPERNICUS)25, the Metoprolol in Idiopathic Dilated 
Cardiomyopathy Study (MDC)26, the Metoprolol CR/XL Randomised Intervention Trial in 
Congestive Heart Failure (MERIT-HF)27, the Study of the Effects of Nebivolol Intervention 
on Outcomes and Rehospitalisation in Seniors with Heart Failure Study (SENIORS)28 and the 
U.S. Carvedilol Heart Failure Study (US-HF)29.   All included studies had low risk of bias, as 
determined using the Cochrane Collaborations Risk of Bias Tool.30 
The CHRISTMAS trial was excluded from this analysis as AF was an exclusion criterion.  
Data were extracted from original source files and additional follow-up outcomes were 
available in seven studies.19-21, 25, 26, 28, 29  The primary outcome was all-cause mortality, 
including an analysis of total mortality where deaths occurred after early study termination or 
following a fixed censor point.  The mean follow-up period until death or censoring was 1.5 
years (SD 1.1) across all studies, which ranged from 0.9 to 5.3 years in the individual trials.  
Major secondary outcomes were CV-death, the composite of all-cause mortality and CV-
hospitalisation, and non-fatal stroke.  Hospitalisation outcomes included the time to 
hospitalisation (any cause), CV-hospitalisation and HF-related hospitalisation, as well as the 
number and duration of CV/HF hospital admissions.  An additional post-hoc defined outcome 
was the composite of CV-death and HF-related hospitalisation.  Drug safety outcomes were 
focused on discontinuation of study drug therapy due to hypotension, bradycardia, renal 
impairment, HF-exacerbation or any adverse event. 
 
Atrial fibrillation/flutter 
The diagnosis of AF or atrial flutter was determined by the baseline electrocardiogram 
(ECG).  Distinguishing between the two atrial arrhythmias was only possible in two trials.20, 
28  Consistent with clinical expectation, flutter accounted for only 4% of the combined group.  
For the purposes of this paper, reference to AF will therefore also include atrial flutter.  
Incident AF was defined as AF during follow-up in patients with sinus rhythm at baseline.  
Follow-up ECGs or adverse event data reflecting new-onset or recurrence of AF were 
available in all studies, with 862 of 13,946 individual patients (6%) missing data.   
 
Statistical analysis 
Data are presented as median and interquartile range (IQR) or percentages.  Estimated 
glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal 
Disease (MDRD) formula, normalised to a body surface area of 1.73 m2.  Three patients had 
missing event dates and were excluded from outcome analyses.  Hospitalisation was not 
recorded for the MDC trial and NYHA class was not explicitly obtained in the 
COPERNICUS study.  As the amount of missing data for other major variables was low, 
there was no requirement for imputation of missing values.   
All analyses followed the principle of intention to treat.  The primary and major secondary 
outcomes were analysed using a stratified Cox proportional hazards regression model.31  This 
is a one-stage fixed effects approach and assumes that all trials are estimating a common 
treatment effect with baseline hazards that vary across studies.  Hazard ratios (HR) and 95% 
confidence intervals (CI) are presented, along with corresponding p-values, with adjustment 
for age, gender and baseline left-ventricular ejection fraction (LVEF), heart rate and use of 
angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB).  
Kaplan Meier plots are used to graph the data (pooling data from all trials).  As the follow-up 
periods in individual studies varied, data were censored at 1200 days.  Heterogeneity for 
pooled outcomes was assessed using the chi-squared test and I2 statistic, with the estimate of 
heterogeneity taken from the inverse-variance fixed-effects two-stage model.32   
A range of sensitivity analyses were performed, including alternative censor points, separate 
exclusion of the BEST and CAPRICORN studies, additional baseline adjustment and random 
effects modelling.33  Exploratory analyses included a per-protocol analysis assessing patients 
who remained on study therapy throughout the trial and factors associated with incident AF 
(using an adjusted logistic regression model as time to diagnosis of AF was not available).   
A two-tailed p-value of 0.05 was considered statistically significant.  Analyses were 
performed on Stata Version 11.2 (StataCorp LP, Texas) and R Version 3.0.2 (R Core Team, 
Vienna).  
Results 
A total of 18,254 individual participants were assessed, of which 13,946 (76.4%) were in 
sinus rhythm at baseline and 3,066 (16.8%) in AF.  Other rhythms (predominantly paced 
rhythm or heart block) accounted for 1,124 (6.2%) and 118 patients had a missing or 
uninterpretable baseline ECG (0.6%).  There were minimal differences in baseline 
characteristics between patients randomised to beta-blockers or placebo in any group (see 
Supplementary Table 1).  A comparison of those in sinus rhythm and AF at baseline is 
presented in Table 1.  The median duration of HF prior to enrolment was 3 years.  Compared 
to those in sinus rhythm, AF patients were 5 years older, with a higher percentage of men.  
There were small differences in systolic blood pressure and GFR but LVEF and heart rate 
were similar.  Patients with AF were more symptomatic, with 72% in NYHA class III/IV 
compared to 62% for those in sinus rhythm.  AF patients had more frequent use of diuretics, 
aldosterone antagonists, digoxin and oral anticoagulants, however 95% in both groups were 
taking ACEi or ARB at baseline.   
 
 
Outcomes according to baseline rhythm 
Including deaths reported after early or date-based study termination, crude mortality rates 
were 20.7% in AF patients (633/3,064) and 16.0% in sinus rhythm (2,237/13,945).  
Considering deaths in the study period only, crude mortality rates were 18.1% in AF patients 
(556/3,064) and 14.5% in sinus rhythm (2,021/13,945).  The most common causes of death in 
both groups were sudden death and death due to heart failure (see Table 2).  Fatal stroke was 
relatively uncommon, although as expected more frequent in patients with AF.   
Table 3 displays pooled hospitalisation data divided into all-cause, CV and HF-related 
hospital admissions.  The total number of hospitalisations and annualised rate per patient 
were higher in AF patients compared to sinus rhythm for all types, with longer average length 
of stay (for CV-hospitalisation 11.9 days in AF versus 9.7 days in sinus rhythm). 
 
 
Efficacy of beta-blocker therapy 
A consistent effect of beta-blockers versus placebo was noted across all death and/or 
hospitalisation outcomes, with benefit demonstrated in sinus rhythm but non-significant 
differences seen in AF patients (see Table 4).  P-values for the interaction of treatment 
efficacy and baseline heart rhythm were significant for each of these outcomes.   
Including all reported deaths, the adjusted HR for all-cause mortality in sinus rhythm was 
0.73 (95% CI 0.67-0.80) and in patients with AF 0.97 (95% CI 0.83-1.14), with a p-value for 
interaction of 0.002.  Kaplan-Meier survival curves are displayed in Figure 1.  Similar results 
were seen for CV-deaths or when restricting analysis to deaths during the study period only.   
For CV-hospitalisation, the adjusted HR in sinus rhythm was 0.78 (95% CI 0.73-0.83) and in 
AF 0.91 (95% CI 0.79-1.04), with a p-value for interaction of 0.05; see Figure 2 for Kaplan-
Meier event curves.  Results were similar for HF-related hospitalisation and the composite 
clinical outcomes (death or CV-hospitalisation and CV-death or HF-related hospitalisation).  
Beta-blocker therapy had no impact on incident non-fatal stroke in either sinus rhythm or AF 
(see Table 4). 
 
 
Sensitivity and exploratory analyses 
Sensitivity analyses for the primary outcome are presented in Supplementary Table 2.  There 
were no observable effects for additional baseline adjustment, the exclusion of specific trials 
or the use of different censor points.  An alternative analysis method using a two-stage meta-
analysis is presented in Figure 3, which resulted in virtually identical hazard ratios to the one-
stage approach using both fixed and random effects modelling.  Importantly, we identified no 
heterogeneity between the individual studies for all-cause mortality in patients with AF 
(I2=0%, p=0.65).   
An exploratory sub-group analysis was performed within the AF cohort for all-cause 
mortality, with no significant interactions identified for a range of baseline variables at 
clinical cut-points, including age, gender, LVEF, NYHA, the control of blood pressure or 
heart rate, and baseline medical therapy (see Figure 4).  We also performed a per-protocol 
assessment for all reported deaths in the AF group.  Compared to the intention-to-treat 
analysis, no difference was identified in the efficacy of beta-blocker therapy in AF patients 
that remained on therapy (HR 0.84; 95% CI 0.68-1.04), with no significant interaction for 
discontinuation of study treatment within the AF group (p=0.09). 
 
 
Incident AF 
In patients with sinus rhythm at baseline, 610 (4.7%) developed AF on a subsequent ECG.  
The factors independently associated with incident AF in an exploratory analysis were 
advanced age, male gender, increased BMI and NYHA class III/IV at baseline (see 
Supplementary Table 3).  Allocation to beta-blockers was associated with a 33% reduction in 
the adjusted odds of incident AF (253/6,722 randomised to beta-blockers developed AF, 
compared to 357/6,362 allocated to placebo). 
 
 
Study drug dosage, discontinuation, adverse treatment effects and heart rate 
There were minimal differences in the dose of study drug achieved according to baseline 
heart rhythm, with overall 84% achieving maximal study dosage in the placebo arm and 73% 
in those randomised to beta-blockers (see Supplementary Table 4).  The attained heart rate 
and change from baseline heart rate were similar in patients with sinus rhythm and AF, 
although interpretation is confounded by lack of measurement in patients who died prior to 
the interim study visit (see Supplementary Table 5).  Rates of study drug discontinuation due 
to adverse effects were identical in patients allocated to either beta-blockers or placebo 
(15%).  No differences in beta-blocker discontinuation rates were identified comparing sinus 
rhythm to AF (see Supplementary Table 6).  The incidence of specific adverse effects causing 
withdrawal of therapy were low (for example hypotension or bradycardia in 1-2%). 
Discussion 
This individual patient analysis has investigated the largest cohort of patients with HF 
due to reduced ejection fraction and AF to-date.  Our principal findings are that in contrast to 
those in sinus rhythm at baseline, patients with HF and AF obtained little or no benefit from 
beta-blockers, with no significant reduction in all-cause mortality, CV-hospitalisation or 
composite clinical outcomes compared to placebo.  The AF group comprised 3,066 
participants with 633 deaths, and although there may still be limited power, this analysis 
suggests that clinical benefit from beta-blockers is unlikely in patients with combined HF and 
AF.  Patients in AF had higher crude rates of death, more frequent hospitalisation and longer 
length of stay compared to those in sinus rhythm.   
 
Heart failure and AF are two common conditions that are increasing in prevalence.  
Although HF incidence has remained static over the past 25 years34, the incidence of AF is 
increasing35 and not simply as a function of the ageing population.36  These two conditions 
frequently co-exist, with observational data suggesting the presence of AF in 14-50% of 
patients with symptomatic HF.14  In HF, atrial remodelling frequently occurs due to sustained 
increases in pressure, volume and neurohormonal stress, making the development of AF more 
likely.  Similarly, AF can lead to HF both as a direct cause (for example in tachycardia-
induced cardiomyopathy) and due to loss of atrioventricular synchrony and impairment in 
diastolic filling.  Heart failure with preserved ejection fraction is as common as the syndrome 
with reduced LVEF2, however no prior trial has examined the impact of pharmacotherapy on 
diastolic function in patients with AF.  However, regardless of the type of HF, the 
combination with AF is known to adversely affect prognosis37 and overall represents a 
massive burden to affected patients, healthcare systems and societies, including substantial 
healthcare costs.38  Hospitalisation in HF is the greatest cost contributor11 and our analysis 
suggests that AF increases both the risk of hospitalisation and length of stay, reinforcing the 
importance of finding efficacious therapies in this population. 
 
The lack of prior focus on optimal management of the combination of HF and AF is 
concerning.  Indeed all current guideline recommendations for treatment of HF with reduced 
LVEF stem from trials predominantly from patients in sinus rhythm.  Guidelines from the 
European Society of Cardiology1 and the American College of Cardiology 
Foundation/American Heart Association2 recommend beta-blocker therapy in patients with 
HF and AF, based on the efficacy demonstrated from the trials assessed in this paper.  Our 
analysis suggests that the substantial benefit identified in patients with sinus rhythm should 
not be extrapolated to those with AF.  The reason for the lack of efficacy of beta-blockers in 
patients with AF may be due to several physiological differences.15  In contrast to sinus 
rhythm, slower heart rates are not associated with improved survival in AF39, although this 
remains to be adequately tested prospectively.  The irregular rhythm in AF is also associated 
with a detrimental impact on systolic and diastolic cardiac function that is independent of 
heart rate.40, 41  There are also structural42 and cellular43 consequences of AF that may impact 
on treatment efficacy.  These observations however, do not fully explain why the positive 
effects of beta-blockers, particularly on myocardial metabolism, do not correspond to 
prognostic benefit in patients with AF, an anomaly that requires further investigation. 
 
Finally it is important to consider the substantial reduction in hospitalisation and death 
that was seen in patients with sinus rhythm.  Rates of beta-blocker uptake amongst HF 
patients in clinical practice have been consistently suboptimal44, 45 and may reflect concern 
about symptom deterioration after initiation of therapy or the poor generalisability of RCT 
data to real-world patients.46  One of the major aims of the Beta-blockers in Heart Failure 
Collaboration was to improve rates of appropriate beta-blocker use by identifying key patient 
groups that benefit most from therapy.  In this regard, use of beta-blockers in patients with 
sinus rhythm is strongly recommended and further sub-group analyses in relation to age, 
gender and diabetes are planned.  We also found a reduction in incident AF in those with 
sinus rhythm treated with beta-blockers.  This confirms a previous tabular analysis of beta-
blocker trials in HF47 and may be an important component of therapeutic benefit in patients 
with sinus rhythm.   
Although we found no evidence that beta-blocker therapy prevents adverse clinical 
events in patients with HF and AF, it did appear safe with no increase in mortality or 
hospitalisation observed.  This should reassure clinicians, particularly for patients with 
another indication for beta-blockers, for example acute myocardial infarction or the need for 
rate control of rapid AF with ongoing symptoms.  However, for the primary reason of 
preventing major adverse cardiovascular outcomes in patients with chronic HF and reduced 
LVEF, beta-blockers do not appear to be effective in those with AF and should no longer be 
considered as standard therapy to improve prognosis. 
 
Strengths & Limitations 
The strength of our analysis was the use of IPD from large, high quality RCTs, with 
near-totality of available randomised data.  We performed careful and methodical data 
extraction from original datasets4, resulting in improved quality of baseline and outcome data 
across trials.  Although the process of IPD meta-analysis is arduous, there are substantial 
benefits including the ability to adjust for covariates and produce time-to-event analyses.16  
We were also able to include post-publication data on mortality, explaining the small 
differences from previously published results in the component RCTs.  We confirmed that 
our conclusions apply across various sub-groups of AF and regardless of meta-analysis 
methodology.  This study provides the most powerful analysis of the efficacy of beta-
blockers in AF ever performed, thereby addressing a key clinical question regarding 
management of this important group of patients with HF. 
As with all meta-analytical techniques, we are limited by the data provided from the 
individual studies.  Although there were missing data for some variables, their impact was 
minimised by extracting data from source datasets with a published data extraction plan.4  As 
previously noted, we were unable to separate those with AF and atrial flutter, however the 
latter made up only a small proportion of patients.  The rate of incident AF was lower than 
expected from clinical practice and may reflect under-reporting, particularly of paroxysmal 
AF.  Our inability to characterise the type, persistence and duration of AF is a limitation.  
Although the validity and reproducibility of LVEF measurement has not been adequately 
demonstrated in patients with AF, we did not see any difference in the variance of LVEF 
comparing those with sinus rhythm and AF.  Finally, heart failure with preserved ejection 
fraction accounts for over half of patients with HF, but RCT data on beta-blockers versus 
placebo in this group are limited.48  Of the studies included in our analysis, only SENIORS 
recruited patients with LVEF≥0.50, which accounted for only 1.8% of the pooled dataset.  
Hence we are unable to comment on the efficacy of beta-blockers according to rhythm status 
for patients with HF and preserved LVEF.  
Conclusion 
In contrast to the beneficial effects noted for patients with sinus rhythm, beta-blocker therapy 
has no or minimal effect on mortality or cardiovascular hospital admission in patients with 
heart failure with reduced ejection fraction and atrial fibrillation.  Based on our results, we 
dispute the preferential use of beta-blockers compared with other rate-control medications 
and emphasise the need for further trials in this common and increasingly important group of 
patients.  
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Table 1:  Pooled characteristics at baseline 
Characteristic 
Sinus rhythm 
n=13,946 
Atrial fibrillation 
n=3,066 
Age, median years (IQR) 64 (54-71) 69 (60-74) 
Women 25.1% 19.4% 
Diabetes mellitus 24.6% 23.1% 
Years with HF diagnosis, median (IQR) 3.0 (1.0-6.0) 3.0 (1.0-7.0) 
LVEF, median % (IQR) 0.27 (0.21-0.33) 0.27 (0.22-0.33) 
NYHA class III/IV 62.6% 72.1% 
Systolic BP, median mmHg (IQR) 123 (110-140) 127 (113-140) 
Diastolic BP, median mmHg (IQR) 78 (70-82) 80 (70-85) 
Heart rate, median bpm (IQR) 80 (72-88) 81 (72-92) 
Body mass index, median kg/m2 (IQR) 27 (24-31) 27 (25-31) 
Estimated GFR, median mL/min (IQR) 64 (52-78) 61 (49-74) 
Any diuretic therapy 85.2% 93.5% 
ACEi or ARB 94.7% 94.5% 
Aldosterone antagonists 8.2% 16.8% 
Digoxin 52.9% 83.5% 
Amiodarone 5.7% 10.4% 
Oral anticoagulation 26.2% 57.8% 
IQR, interquartile range; LVEF, left-ventricular ejection fraction; NYHA, New York Heart Association functional class; BP, blood pressure; GFR, glomerular filtration rate; ACEi, 
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.  Within group characteristics according to treatment allocation are presented in Supplementary Table 1.  
Missing data were present for the following variables: Diabetes mellitus (n=993); Years with HF (n=2784); LVEF (n=76); NYHA class (n=2,376); Systolic BP (n=10); Diastolic BP 
(n=17); Heart rate (n=8); Body mass index (n=150); and GFR (n=735). 
 
  
Table 2:  Cause of death 
 
Cause of death 
Number of deaths (percentage of group) 
Sinus rhythm Atrial fibrillation 
Acute myocardial infarction 126 (5.6%) 13 (2.1%) 
Sudden death 927 (41.4%) 231 (36.5%) 
Heart failure 539 (24.1%) 184 (29.1%) 
Other cardiac cause 59 (2.6%) 11 (1.7%) 
Stroke 43 (1.9%) 27 (4.3%) 
Other vascular cause 99 (4.4%) 38 (6.0%) 
Non-cardiovascular 180 (8.1%) 45 (7.1%) 
Unknown 264 (11.8%) 84 (13.3%) 
Total deaths 2,237 / 13,946 (16.0%) 633 / 3,066 (20.7%) 
Includes all deaths, including those reported after early termination/study closure. 
  
Table 3:  Hospitalisation 
Hospitalisation type Pooled data for sinus rhythm Pooled data for atrial fibrillation 
All-cause hospitalisation 
    Percentage with 1 or more admission 
    Average number of admissions per patient 
    Annualised hospitalisation rate per patient 
 
37.7% 
0.78 (range 0-26) 
0.86/year 
 
40.1%  
0.79 (range 0-26) 
0.94/year 
CV-hospitalisation 
    Percentage with 1 or more admission 
    Average number of admissions per patient 
    Annualised hospitalisation rate per patient 
    Average length of stay * 
 
25.7% 
0.45 (range 0-16) 
0.52/year 
Mean 9.7, median 6 days (range 1-368) 
 
28.9%  
0.49 (range 0-14) 
0.60/year 
Mean 11.9, median 8 days (range 1-179) 
HF-related hospitalisation 
    Percentage with 1 or more admission 
    Average number of admissions per patient 
    Annualised hospitalisation rate per patient 
    Average length of stay * 
 
16.4% 
0.30 (range 0-16) 
0.36/year 
Mean 9.8, median 6.5 days (range 1-148) 
 
21.0% 
0.36 (range 0-14) 
0.41/year 
Mean 12.0, median 8 days (range 1-179) 
Note that presented data do not account for differences in baseline demographics between groups.  *Average of first five hospitalisations for a CV/HF cause in those patients with at 
least one admission.   
 
  
Table 4:  Primary and secondary adverse outcomes 
Outcome 
Number of 
events/sample 
size 
Sinus rhythm;  
Beta-blockers versus placebo 
Atrial fibrillation; 
Beta-blockers versus placebo 
Interaction; 
AF versus sinus rhythm 
  HR (95% CI) * p-value HR (95% CI) * p-value p-value 
All-cause mortality (including all 
reported deaths) 2870 / 17009 0.73 (0.67, 0.80) <0.001 0.97 (0.83, 1.14) 0.73 0.002 
All-cause mortality (deaths 
during study period) 2577 / 17009 0.73 (0.67, 0.80) <0.001 0.93 (0.79, 1.10) 0.43 0.01 
CV-death (including all reported 
deaths) 2297 / 17009 0.72 (0.65, 0.79) <0.001 0.92 (0.77, 1.10) 0.35 0.02 
First CV-hospitalisation 4374 / 16644 0.78 (0.73, 0.83) <0.001 0.91 (0.79, 1.04) 0.15 0.05 
Death or CV-hospitalisation 5670 / 16644 0.76 (0.72, 0.81) <0.001 0.89 (0.80, 1.01) 0.06 0.01 
First HF-related hospitalisation 2872 / 16644 0.71 (0.65, 0.77) <0.001 0.91 (0.78, 1.07) 0.26 0.005 
CV-death (during study period) 
or HF-related hospitalisation † 4151 / 16644 0.70 (0.65, 0.75) <0.001 0.90 (0.79, 1.03) 0.13 0.001 
Non-fatal stroke 296 / 16644 1.02 (0.78, 1.32) 0.91 1.04 (0.66, 1.63) 0.87 0.94 
MDC does not contribute to analyses involving hospitalisation or incident stroke.  *Hazard ratios derived from the one-stage Cox regression model, stratified by study and adjusted 
for the following variables (where applicable, missing data in brackets): Age, gender, baseline LVEF (n=76 missing), baseline heart rate (n=8 missing) and use of ACEi/ARB.  
†Outcome was not pre-specified.  
Supplementary Table 1:  Baseline demographics according to treatment allocation 
Characteristic 
Sinus rhythm (n=13,946) Atrial fibrillation (n=3,066) Other (n=1,242) * 
Beta-blocker  
(n=7,123) 
Placebo 
(n=6,823) 
Beta-blocker 
(n=1,523) 
Placebo 
(n=1,543) 
Beta-blocker 
(n=640) 
Placebo 
(n=602) 
Age, median years (IQR) 64 (54-72) 63 (54-71) 69 (60-75) 69 (61-74) 69 (60-76) 70 (62-76) 
Women 24.7% 25.4% 18.9% 19.8% 20.6% 17.8% 
Diabetes Mellitus 24.3% 24.8% 21.9% 24.3% 29.8% 30.4% 
Years with HF diagnosis, median (IQR) 3.0 (1.0-6.0) 3.0 (1.0-6.0) 3.0 (1.0-7.0) 4.0 (2.0-7.0) 5.0 (2.0-9.0) 5.0 (2.0-10.0) 
LVEF, median % (IQR) 0.27 (0.21-0.33) 0.27 (0.21-0.33) 0.27 (0.21-0.33) 0.27 (0.22-0.33) 0.23 (0.19-0.30) 0.22 (0.18-0.30) 
NYHA class III/IV 62.6% 62.5% 72.2% 72.1% 67.5% 63.8% 
Systolic BP, median mmHg (IQR) 123 (110-140) 123 (110-140) 126 (113-140) 127 (114-140) 120 (109-130) 120 (110-133) 
Diastolic BP, median mmHg (IQR) 78 (70-82) 78 (70-83) 80 (70-85) 80 (70-85) 72 (65-80) 72 (66-80) 
Heart rate, median bpm (IQR) 80 (72-88) 80 (72-88) 81 (72-92) 81 (73-92) 76 (70-85) 76 (70-83) 
Body mass index, median kg/m2 (IQR) 27 (24-31) 27 (24-31) 28 (25-31) 27 (25-31) 26 (24-29) 27 (24-30) 
Estimated GFR, median mL/min (IQR) 65 (52-78) 64 (51-78) 61 (49-74) 60 (48-73) 54 (41-64) 52 (42-64) 
Any diuretic therapy 85.1% 85.4% 93.1% 93.9% 92.2% 94.8% 
ACEi or ARB 95.1% 94.4% 95.3% 93.8% 93.5% 93.1% 
Aldosterone antagonists 8.1% 8.2% 16.8% 16.7% 15.8% 14.2% 
Digoxin 51.9% 53.9% 83.7% 83.3% 67.6% 70.2% 
Amiodarone 6.2% 5.3% 11.2% 9.7% 17.5% 17.2% 
Oral anticoagulation 26.1% 26.3% 58.3% 57.3% 39.9% 40.4% 
See Table 1 legend for missing data report.  * Includes heart block (41.1% of group), paced rhythm (49.4%) and patients with a missing or uninterpretable baseline ECG (9.5%).  
Supplementary Table 2:  Sensitivity analyses for primary outcome 
Time to all-cause mortality  
(all reported deaths) 
Sinus rhythm;  
Beta-blockers versus placebo 
Atrial fibrillation; 
Beta-blockers versus placebo 
Interaction; 
AF versus sinus rhythm 
HR (95% CI) p-value HR (95% CI) p-value p-value 
Main adjusted analysis  
(all trials, censor at 1200 days) 
0.73 (0.67, 0.80) <0.001 0.97 (0.83, 1.14) 0.73 0.002 
Additional adjustment for 
baseline use of digoxin and oral 
anticoagulation 
0.73 (0.67, 0.80) <0.001 0.97 (0.83, 1.14) 0.75 0.002 
Exclusion of BEST trial 0.66 (0.60, 0.74) <0.001 1.03 (0.86, 1.24) 0.74 <0.001 
Exclusion of CAPRICORN trial 0.72 (0.66, 0.79) <0.001 0.98 (0.83, 1.15) 0.81 0.002 
Censor at 770 days 0.72 (0.66, 0.79) <0.001 1.00 (0.84, 1.18) 0.98 <0.001 
Censor at 365 days 0.69 (0.61, 0.77) <0.001 0.97 (0.79, 1.19) 0.75 0.005 
Random effects model 0.72 (0.64, 0.80) <0.001 0.96 (0.80, 1.14) 0.62 0.002  
Hazard ratios derived from the adjusted one-stage Cox regression model, stratified by study.  
  
Supplementary Table 3:  Factors associated with incident AF 
Variable (binary cut-point) 
Incident AF in patients with sinus rhythm at baseline 
OR (95% CI) for model 
with binary variables * 
p-value for model with 
binary variables * 
p-value for model with 
continuous variables † 
Allocation to beta-blockers vs. placebo 0.67 (0.57, 0.79) <0.001 <0.001 
Age (≥70 years) 1.77 (1.44, 2.17) <0.001 <0.001 
Women vs. men 0.71 (0.58, 0.88) 0.001 0.001 
Ischaemic vs. non-ischaemic cardiomyopathy 0.97 (0.80-1.18) 0.76 0.46 
LVEF (≤0.35) 0.84 (0.63, 1.11) 0.21 0.87 
Hypertension (≥140/90 mmHg) 0.98 (0.74, 1.29) 0.87 0.97 
Body mass index (≥30 kg/m2) 1.23 (1.00, 1.52) 0.05 <0.001 
NYHA class (III/IV vs. I/II) 1.47 (1.11, 1.93) 0.007 0.02 
Odds ratios (OR) derived from a multivariate logistic regression model with binary dependent variables, additionally adjusted for study.  † Modelled using continuous variables, 
where applicable. 
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Supplementary Table 4:  Study drug dosage  
Treatment arm 
Pooled average dose achieved as a percentage of 
maximal dose* 
Sinus rhythm Atrial fibrillation 
Placebo 84.1% 83.7% 
Beta-blocker 73.5% 72.1% 
* Achieved at the interim time point for each study, accounting for the differences in maximum planned dosage 
between studies.  Data not available for the BEST trial with an additional 5,413 patients missing data on interim 
dosage (total n=11,599). 
 
  
  
Supplementary Table 5:  Change in heart rate 
 n 
Baseline heart rate  
(bpm) 
Attained heart rate  
(bpm) 
Change from baseline  
(bpm) 
Placebo Beta-blocker Placebo Beta-blocker Placebo Beta-blocker 
All patients surviving 
to interim follow-up 14,796 80 (72, 88) 80 (72, 88) 78 (70,88) 68 (60, 76) -2 (-10, 6) -12 (-20,-4) 
According to baseline heart rhythm: 
Sinus rhythm 12,204 80 (72, 88) 80 (72, 88) 78 (70, 87) 68 (60, 76) -2 (-10, 6) -12 (-20, -4) 
Atrial fibrillation 2,592 81 (72, 92) 81 (72, 92) 80 (79, 90) 70 (62, 80) -2 (-12, 6) -12 (-22, -1) 
Data presented are median heart rates (IQR) pooled from individual patient data at the interim study time-point.  
Median time to follow-up heart rate 0.5 years (IQR 0.3-0.6) with n=118 missing data. 
  
 Supplementary Table 6:  Beta-blocker discontinuation 
Discontinuation of beta-blockers Sinus rhythm Atrial fibrillation 
   - due to any adverse event* 1051 (14.4%) 231 (15.2%) 
   - due to hypotension† 65 (1.2%) 14 (1.2%) 
   - due to bradycardia† 68 (1.3%) 18 (1.6%) 
   - due to HF exacerbation* 262 (3.8%) 71 (4.9%) 
   - due to renal impairment† 22 (0.4%) 8 (0.7%) 
   - due to respiratory dysfunction† 43 (0.8%) 4 (0.4%) 
Presented as absolute number (percentage within group).  * Data available for all trials (total n=8,813 allocated to 
beta-blockers).  † Data not available for MERIT-HF, CIBIS-I and MDC (total n=6,445 allocated to beta-blockers). 
  
  
 Figure 1 
 
Kaplan Meier survival curve for sinus rhythm and AF comparing beta-blocker therapy 
versus placebo 
Unadjusted survival curves for all reported deaths.  Hazard ratios are derived from the adjusted 
one-stage Cox-regression model, stratified by study. 
 
 
 
 
 
  
 Figure 2 
 
Figure 2:  Kaplan Meier event curve for cardiovascular hospitalisation in sinus rhythm 
and AF comparing beta-blocker therapy versus placebo  
Unadjusted event curves for CV-hospitalisation during the study period.  Hazard ratios are 
derived from the adjusted one-stage Cox-regression model, stratified by study. 
 
 
 
 
  
 Figure 3 
 
Figure 3:  Two-stage adjusted meta-analysis for all-cause mortality 
Cox regression models in sinus rhythm and AF, adjusted for age, gender, LVEF, heart rate and 
use of ACEi/ARB, meta-analysed using a fixed-effects approach.  Analysis includes all reported 
deaths, censored at 1200 days.  Heterogeneity was significant for sinus rhythm (I2=56%, 
p=0.016) but not for AF (I2=0%, p=0.65). 
 
 
 
 Figure 4 
 
Figure 4:  Sub-group analysis of all-cause mortality in AF patients comparing beta-blocker 
therapy versus placebo 
Exploration of treatment efficacy for patients with AF according to baseline 
variables/measurements.  Dashed line is the overall effect of beta-blockers versus placebo in AF 
patients.  Hazard ratios and interaction p-values derived from the one-stage Cox regression 
model, stratified by study. 
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